Protext Mobility, Inc. engaged in the development of pharmaceutical applications for the highly bioavailable Phytofare® catechin complex discussed the potential for Phytofare® in treating type II Diabetes. Data from in vitro and in vivo studies suggest that green tea catechins, in particularly EGCG, exert anti-obesity effects via several mechanisms including inhibition of adipocyte differentiation and proliferation, reduction of fat absorption, and the reduction in fat mass, tricylglycerides, free fatty acids and total cholesterol. The majority of human intervention studies investigating glucose homeostasis further demonstrate improved glucose levels in response to green tea catechins with potential anti-obesity, anti-diabetic and cardio-protective applications. The greatly improved absorption (bioavailability) of Phytofare® should address the blood plasma barrier issues to help regulate the metabolic issues associated with type II Diabetes.